Sequestration of tumor necrosis factor-a (TNFa) by TNFreceptor immunoglobulin G (IgG)-Fc fusion proteins can limit heart failure progression in rodent models. In this study we directly injected an adeno-associated viruses (AAV)-2 construct encoding a human TNF receptor II IgG-Fc fusion protein (AAV-TNFRII-Fc) into healthy baboon hearts and assessed virally encoded gene expression and clinical response. Adult baboons received direct cardiac injections of AAV-TNFRII-Fc (B5 Â 10 12 viral/genomes/baboon) or an equivalent dose of AAV-2 empty capsids, and were analyzed after 5 or 12 weeks. Viral genomes were restricted to the myocardium, and routine analyses (blood cell counts, clinical chemistries) remained unremarkable. Echocardiograms were unchanged but electrocardiograms revealed marked ST-and T-wave changes consistent with myocarditis only in baboons receiving AAV-TNFRII-Fc. TNFRII serum levels peaked at B3 times the baseline levels at 1-2 weeks postinjection and subsequently declined to baseline levels. TNFRII-Fc protein and transcripts were detected in the heart at harvest. After AAV injection, anti-AAV-2 antibody levels increased in all baboons, while anti-TNFRII-Fc could not be detected. Baboons that received AAV-TNFRII-Fc developed myocardial infiltrates including CD8+ cells. Thus, a cellular immune response to cardiac delivery of AAV encoding foreign proteins may be an important consideration for AAV-based cardiac gene therapy.
Introduction
In the United States, nearly 4 million people have congestive heart failure (CHF), and another 400 000 are newly diagnosed each year. Despite advances in pharmacologic support and cardiac assist-device placement, CHF presents a grave prognosis, with a 5-year mortality of 450%. Thus, the identification of novel therapeutic targets, agents and methods of drug delivery to improve therapy for CHF remains an important objective.
Heart failure is associated with increased levels of myocardial and circulating proinflammatory cytokines, including tumor necrosis factor-a (TNFa).
1 TNFa adversely modulates cardiomyocyte cellular signaling, contractile function and cardiac extracellular matrix remodeling. 2 In mice, cardiac-specific overexpression of TNFa causes dilated cardiomyopathy, while endogenously produced TNFa contributes to postinfarction remodeling. 3, 4 Genetic ablation of TNF receptors, or administration of anti-TNFa antibodies, improves cardiac function and limits remodeling in mouse models of heart failure and myocardial infarction. [4] [5] [6] A gene therapy approach that expresses soluble TNF-receptor derivatives which sequester TNFa can limit cardiac remodeling and heart failure progression in rodent models. 7, 8 In humans, systemic delivery of human soluble TNFa receptor II-Fc fusion protein (TNFRII-Fc, etanercept) via repetitive subcutaneous injection reduces joint inflammation and improves symptoms in autoimmune diseases including rheumatoid arthritis (RA) and psoriasis. 9, 10 However subcutaneous delivery of etanercept did not show therapeutic benefit in humans with CHF. 11 Cardiac expression of potentially therapeutic proteins through virally mediated gene transfer into the myocardium is a potential strategy for the treatment of heart disease. 12, 13 Benefits of this approach over recurrent therapeutic interventions may include locally higher levels of protein expression, fewer systemic side effects and long-term myocardial expression of the desired protein when using vectors such as adeno-associated viruses (AAV). However, the potential adverse effects of the viral vector or the cardiac-expressed proteins that they encode remain incompletely understood. While the cardiac expression from AAV vectors delivered into the systemic circulation of neonatal primates has been reported, 14 the response to direct delivery of AAV-based vectors into the adult primate heart has not been investigated. The current study was designed to test the safety of TNFRII-Fc expression when encoded by an AAV-2 vector and directly injected into baboon hearts. Surprisingly, we observed that while baboons receiving a direct cardiac injection of AAV-2 empty capsid demonstrated no pathologic abnormalities, baboons receiving AAV-2 encoding TNFRII-Fc developed electrocardiographic and histologic evidence of myocarditis.
Results

AAV-TNFRII-Fc directs TNFRII-Fc expression
To confirm expression of TNFRII-Fc protein from AAV-TNFRII-Fc, HEK293 cells were infected and analyzed by western blot (Figure 1a ). Anti-human immunoglobulin G (IgG) detected a B75 kDa protein (expected size for TNFRII-Fc) only in cell extracts and media from AAV-TNFRII-Fc-infected cells. Enzyme-linked immunosorbent assay (ELISA) detected B20 ng ml À1 of human soluble TNFRII (sTNFR) in media from infected, but not uninfected cells.
To assess expression in vivo, hindlimb muscles of immune-incompetent mice were injected with 3 Â 10 Figure 1b) . A protein detected by anti-human sTNFRII was present in the leg muscles of mice receiving AAV-TNFRII-Fc, with none detected in controls ( Figure  1c ). Anti-human IgG stained leg muscles only in mice that received AAV-TNFRII-Fc (Figure 1d ). Figure 2 ). These changes included marked T-wave inversions and/or ST depressions in the precordial leads that persisted for the duration of follow-up. While mild T-wave inversions were noted in the inferior leads in all animals at baseline and throughout follow-up, no precordial T-wave changes occurred in baboons receiving empty capsids ( Figure 2 and online Supplementary 
sTNFRII expression
Weekly serum samples were collected postsurgery and sTNFRII expression was determined by anti-human sTNFRII ELISA. (Figure 4a ). For the first three weeks postsurgery, baboons receiving AAV-TNFRII-Fc had significantly (Po0.02) elevated serum sTNFRII levels (absolute range 231-743 pg ml À1 ) relative to the baseline serum levels (186746 pg ml Direct injection of AAV-2 into baboon hearts CF McTiernan et al levels (defined as 42 s.d. above the empty capsid group mean). In addition, both noninjected sites were slightly elevated. In the baboons analyzed at 12 weeks postinjection with AAV-TNFRII-Fc, one (402) had markedly elevated sTNFRII levels, relative to the empty capsid group, in both the low-and high-dose-injected sites. The second (202) had sTNFRII levels nominally elevated relative to the empty capsid group. Baboon 402 also had markedly elevated sTNFRII expression in the noninjected site, whereas baboon 202 did not.
As the human sTNFRII ELISA may also detect endogenous baboon TNFRII, cardiac tissue samples were examined for AAV-TNFRII-Fc transcripts (Figure 5a ). The AAV-TNFRII-Fc nucleotide sequence predicted a viral transcript of B2.8 kb. In northern blots (utilizing RNA from high-dose-injected sites) hybridized to a TNFRII-Fc probe, the four hearts that received AAV-TNFRII-Fc showed variable expression of a B3 kb transcript that was absent in the two hearts receiving empty capsid. A similar sized transcript was detected with a WPRE probe (specific for the AAV-encoded TNFRII-Fc transcript) in the sample most reactive to the TNFRII-Fc probe (Figure 5a ). Primers specific to the 5 0 -UTR/TNFRII region of the viral transcript were also 
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CF McTiernan et al used in reverse-transcription-PCR to detect spliced viral TNFRII-Fc transcripts in heart RNA samples. A B200 bp fragment (predicted for a spliced transcript from AAV-TNFRII-Fc) was detected in all heart RNA samples from baboons, which had received AAV-TNFRII-Fc, but not in either heart, which had received empty capsids (Figure 5b ).
Anti-AAV and anti-TNFRII-Fc antibodies
The kinetics of serum sTNFRII levels suggested the development of immune responses to either AAV capsid proteins or the human TNFRII-Fc protein, with a subsequent immune-mediated decrease in TNFRII-Fc expression. To assess the immune response to AAV-2 capsid proteins, serum from pre-and 5-week post-AAV injection were tested for AAV neutralizing antibodies (NAB; Supplementary Table 4 ). All pre-injection sera were negative (no NAB at serum dilutions of 1:10) except for baboon 202 which had AAV-2 NAB at 1:20 dilution. The 5-week postinjection sera were all NAB positive, with inhibition detected at dilutions ranging from 1:80 to 1:1280. Baboon 202, which had the highest baseline NAB titer, developed the highest NAB titer after AAV-TNFRIIFc delivery. Baboon serum samples were also examined for the development of anti-AAV capsid protein and anti-TNFRII-Fc antibodies. Due to the cross-reactivity of anti-baboon IgG antibodies to the human Fc portion of TNFRII-Fc, baboon IgG was isolated from presurgery and 5-week postsurgery serum and labeled with biotin. Interaction of the baboon IgG with filters containing AAV capsids was then detected via an avidin-horseradish peroxidase (HRP) conjugate. As observed with NAB measurements, baboons developed anti-AAV-2 antibodies after cardiac injections with either empty capsids or AAV-TNFRII-Fc (Figure 6a ). Baboon biotinylated IgG samples were also interacted with filters containing etanercept (1 ng-100 mg), which duplicates the protein sequences encoded by AAV-TNFRII-Fc. However, antietanercept IgG was not detected in any baboons at either 5 or 12 weeks after virus injections (Figure 6b ).
Histology and assessment of infiltrating cells
Routine hematoxylin and eosin (H&E) examination revealed minimal abnormalities at the uninjected (Figure  7a ), low- (Figure 7b ) or high-dose (Figure 7c ) sites in baboons receiving empty capsids. Baboons receiving AAV-TNFRII-Fc and examined after 5 weeks (Figures 7d-f) or (Figures 7g-i) showed moderate to severe myocardial infiltrates at both the high-and low-dose sites. Fat droplets and fibrotic regions were also observed. Locally intense infiltrates were occasionally observed at noninjected sites in these baboons. To assess for a possible cytotoxic T-cell response, immunofluorescent staining was performed with anti-CD8 (Figure 8 ). These studies revealed few CD8+ cells at any site in hearts from baboons, which received empty capsids (Figures 8a and  b) . In contrast, animals that received AAV-TNFRII-Fc (Figures 8c and d) showed a marked increase in CD8+ cells at the site of virus injection, and to a lesser extent at noninjected sites. Similar observations were also observed in animals analyzed at 12 weeks after injection of AAV-TNFRII-Fc (Figures 8e and f ).
Discussion
The current study was designed to test the cardiac and systemic responses to the expression of human TNFRIIFc encoded by an AAV-2 vector that was directly injected into the myocardium of healthy, nonhuman primates. Baboons received injections of either AAV-2 empty capsids or AAV-2 particles encoding human TNFRII-Fc, and were followed for 5-12 weeks. The animals tolerated the surgical procedures well and showed no significant changes in blood chemistries or leukocyte counts relative to presurgical values. Echocardiographic studies revealed no cardiac structural or functional response to viral injection. Genome distribution studies showed restriction of AAV genomes to the heart with minimal systemic viral genome presence at 5-week postinjection. Within the heart, viral genomes were not restricted to the injection site. Notably, electrocardiograms and histology suggested the development of myocarditis in all baboons that received AAV-TNFRII-Fc, but not in baboons that received empty capsids. Serum sTNFRII levels were elevated in baboons receiving AAV-TNFRII-Fc by the first postsurgical week. A progressive decline followed, suggesting a decrease in the cardiac expression of TNFRII-Fc encoded by the injected AAV-2. Cardiac expression of virus-encoded TNFRII-Fc transcripts and/or sTNFRII protein was evident at both 5 and 12 weeks postsurgery (at a time when serum sTNFRII had declined), although expression levels varied considerably. This decrease in serum levels of AAV-encoded protein contrasts with reports in which (1) skeletal muscle-injected AAV-2 encoding rhesus erythropoietin produced supraphysiologic erythropoietin serum levels for over 400 days in B50% of treated rhesus monkeys, 15 (2) skeletal muscle-injected AAV2/1 encoding rat TNFR-Fc produced high serum levels (micrograms per ml) of rat TNFR-Fc in immunocompetent rats for months 16 and (3) our observations of prolonged human sTNFRII serum expression in nude mice receiving skeletal muscle injection of AAV-TNFRII-Fc.
Previous reports which utilized either direct systemic infusion or a 'gene therapy' directed overexpression of either the sTNFRII-Fc or sTNFRI-Fc proteins observed a reduction of cardiac inflammation in rodent or canine models, which argues against a direct stimulation of myocarditis simply through increased presence of these TNF-neutralizing proteins.
7,8,17 Thus, we hypothesized AAV antibodies are present in B70-80% of humans and other primates. 18 While a minority of humans (o2%) develop non-NABs to etanercept, 19 baboons develop etanercept-NABs after repetitive subcutaneous injections. 20 In this study, baboons responded to AAV antigens with the development of anti-AAV antibodies. Preexistent AAV NAB was detected in one baseline sample (202), and increased after injection of AAV-2 TNFRII-Fc. Interestingly, in this baboon, the resultant serum and cardiac TNFRII protein levels were the lowest among the four baboons that received AAV-TNFRII-Fc, resembling observations that preexisting immunity to AAV could diminish efficacy of AAV-mediated gene transfer. 21 This observation may have important relevance to cardiac-directed AAV-based gene therapy in humans. However, we could not demonstrate the development of anti-TNFRII-Fc antibodies in baboons that received AAV-TNFRII-Fc, suggesting that a cellular immune response produced the decrease in TNFRII-Fc expression.
Histologic examination revealed myocardial infiltration in baboons receiving AAV-TNFRII-Fc, with little or no infiltration in hearts receiving empty capsids. This infiltration reinforces the interpretation of ECG abnormalities as consistent with myocarditis. Immunofluorescent microscopy revealed cardiac infiltrating CD8+ cells only in hearts that received AAV-TNFRII-Fc, suggesting a cytotoxic T-cell response to the expression of human TNFRII-Fc. The immune response to foreign antigens encoded by AAV vectors is influenced by many factors; viral load, tissue location of viral delivery, cellular destination of the encoded protein (secreted, intracellular, membrane-bound) and the encoded protein antigenicity. [22] [23] [24] [25] Interestingly, delivery of AAV-2 encoding chicken ovalbumin to mouse skeletal muscle produced a transient rise and fall (within 4 weeks) of serum chicken ovalbumin, development of anti-ovalbumin antibodies and a cytotoxic T-cell infiltration into the injected skeletal muscle, presumably mediating the transient expression of the virally encoded protein. 25 The kinetics of serum sTNFRII produced after injection of AAV-2 encoding the secreted human TNFRII-Fc into the baboon myocardium, and the presence of a CD8+ cardiac cellular infiltrate, led us to hypothesize a similar immune response to secreted human TNFRII-Fc in the baboon myocardium.
The absence of detectable anti-TNFRII-Fc antibodies in baboons that received AAV-TNFRII-Fc contrasts with the reported development of anti-etanercept antibodies in baboons that received subcutaneous etanercept. 20 Formally, we cannot rule out that either our assay was too insensitive to detect baboon anti-human sTNFRII-Fc antibodies, or that the use of protein-A to select IgG antibodies excluded the antibody class reactive to human sTNFRII-Fc. Nonetheless, we could use this method (directly biotinylated baboon IgG) to detect the development of anti-AAV antibodies. More speculatively, we hypothesize that etanercept delivered 'exogenously' via subcutaneous injection may be treated like vaccine or pathogen antigens and become processed for presentation on major histocompatibility complex (MHC) class II molecules to T-helper cells, with subsequent B-cell activation and anti-etanercerpt production. However, AAV-encoded TNFRII-Fc may be processed as an 'endogenously' expressed foreign antigen (resembling virally encoded proteins), which may favor presentation on MHC class I molecules and formation of a CD8+ cytotoxic T-cell response, with little production of novel antibodies. 
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One limitation of this study is the inability to differentiate between a CD8+ T-cell response to the human TNFRII-Fc protein versus the AAV-2 capsid proteins. The MHC class I presentation of AAV-2 capsid proteins has been hypothesized to underlie a CD8+ T-cell-mediated destruction of AAV-transfected human hepatocytes that expressed human factor IX. 26 However, in the current study, baboons which received AAV-2 empty capsids did not demonstrate a CD8+ T-cell infiltrate, suggesting that the AAV-encoded human TNFRII-Fc elicited the CD8+ T-cell infiltration. Clearly, the utilization of additional reporter viruses, and a more detailed identification of AAV capsid or encoded protein epitopes, which induce a cardiac cellular infiltrate are important goals for future investigations.
In murine models of autoimmune and viral-induced myocarditis, blockade of TNF signaling can reduce cardiac infiltration. 27, 28 Thus one might have anticipated that expression of the human TNFRII-Fc would blunt myocarditis in the baboon heart. However, as serum sTNFRII levels only reached B3 times the baseline levels of baboon sTNFRII, we suggest that insufficient TNFRII-Fc serum levels were achieved to block this TNF-dependent process. For comparison, to achieve suppression of a TNF-dependent pathologic process such as RA, humans treated with subcutaneous etanercept achieve serum levels 5-to 10 000-fold higher than that attained in the baboons of this study. 29 The development of myocarditis in baboons receiving AAV-2 TNFRII-Fc may be considered an adverse event that could lead to development of overt cardiac dysfunction, or exacerbation of underlying disease. The absence of infiltrates in baboon hearts, which received AAV-2 empty capsids suggests a cellular immune response to the virally encoded human TNFRII-Fc. One might consider whether the immune responses of baboons to human TNFRII-Fc are relevant to the impact of etanercept on human heart failure. Etanercept has been associated with a low incidence of new onset heart failure among patients with no known heart failure risk factors. 30 In addition, the Randomized Etanercept Worldwide Evaluation study failed to show a functional or survival benefit in NYHA class II-IV patients who received etanercept.
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Patients who receive subcutaneous etanercept develop serum levels that are several thousand-fold higher than that observed in baboons with cardiac expression of TNFRII-Fc. 29 However, it is more difficult to relate the cardiac levels of TNFRII-Fc produced in baboons injected with AAV-TNFRII-Fc to the cardiac levels attained in humans after subcutaneous injection of etanercept. Interestingly, some patients develop an infrequent and transient injection site reaction to high-dose subcutaneous etanercept (B25 mg ml
À1
) that is accompanied by a CD8+ T-cell infiltrate. 31 It is unclear whether the immune response in baboons with cardiac expression of a virally encoded human TNFRII-Fc is related to the mechanisms by which subcutaneous delivery of etanercept is ineffective in patients with CHF. However, we acknowledge that this study does not rule out the possibility that locally high levels of TNFRII-Fc could be directly toxic to the myocardium.
This study demonstrated that the delivery of an AAV vector encoding a potentially therapeutic protein could be achieved in the adult primate myocardium via direct injection. We observed that such procedures can be accompanied by potentially adverse immune responses that may not be adequately revealed in rodent models. 32 Furthermore, preexisting anti-AAV antibodies may limit the expression of the AAV-encoded therapeutic gene. Clearly, these studies in primate models must be conservatively interpreted due to the limited number of baboons that were treated with either empty capsid or protein-encoding virus. However, the results emphasize the importance of considering the potential immune responses to novel proteins utilized for cardiac gene therapy, and the importance of non-rodent preclinical models in testing their safety.
Materials and methods
Virus construction and characterization
Nucleotide sequencing of the AAV-TNFRII-Fc plasmid confirmed that it encoded amino acids 1-257 of human TNFRII (GenBank BT019927.1) fused to the C-terminal 232 amino acids of human IgG mu heavy chain (GenBank BC041037.1). 33 TNFRII-Fc expression was driven by the cytomegalovirus (CMV) immediate-early promoter. AAV-2 encoding TNFRII-Fc (AAV-TNFRII-Fc), and AAV-2 empty capsids were produced in HEK293 cells and purified (see online Supplement information). Viral titers (viral genomes per ml) were determined by vector genome number. 34 AAV2 empty capsid particle numbers were estimated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis by comparison to samples with known viral titers as determined by vector genome number. TNFRII-Fc expression from AAV-TNFRII-Fc was confirmed after infection of HEK cells or injection into nude mouse skeletal muscle. TNFRII-Fc protein expression was determined by ELISA (human sTNFRII, R&D Systems, Minneapolis, MN, USA), which does not recognize murine TNFRII.
Experimental design
Baboons (Papio anubis, n ¼ 6, male, 30-40 kg) were obtained from the Southwest Foundation for Biomedical Research (San Antonio, TX, USA). Baseline analyses included routine blood cell counts, blood chemistries, 12 lead ECG, CXR and TTE. For surgical delivery of virus, the heart was exposed via a left lateral thoracotomy (see online supplement for details). Two 3 Â 3 cm grid stencils were placed over the lateral and anterior wall of the left ventricle, and nine sites within each grid were injected with 0.1 ml of either AAV-TNFRII-Fc or AAV empty capsids. In four baboons, one grid was randomly assigned to receive low-dose (5 Â 10 11 viral genomes per ml) and the other high-dose (5 Â 10 12 viral genomes per ml) injection of AAV-TNFRII-Fc. Empty capsids at an equivalent particle per ml concentration were injected into two baboons as controls. After surgery, blood samples were obtained weekly (4 Â ) and every other week thereafter, while ECGs, CXRs and TTEs were performed every other week until baboons were killed. Two baboons receiving AAV-TNFRII-Fc, and one receiving AAV empty capsids were killed at each time point (5 or 12 weeks postsurgery). All animal and biosafety procedures were reviewed and approved by the University of Pittsburgh Institutional Animal Care and Use, and Institutional Biosafety Committees. copies per reaction). For Southern blot analyses, baboon heart DNA was digested with EcoRI, and probed with radiolabeled TNFII-Fc DNA (see online Supplementary information).
RNA analyses
Standard methods were used to isolate RNA, prepare radiolabeled TNFRII-Fc-specific probes and perform northern blots. Reverse transcription-mediated PCR was performed with TNFRII-Fc-specific primers and analyzed by gel electrophoresis (see online Supplement information).
AAV neutralizing antibodies
Neutralizing antibody titers were determined by testing the ability of baboon sera to inhibit reporter rAAV2-LacZ transduction of C12 cell (see online Supplement information).
Anti-AAV and anti-TNFRII-Fc
Immunoglobulin G (IgG) was purified from baboon serum and biotinylated. To detect anti-AAV antibodies, filters containing serial dilutions of AAV-2 were challenged with biotinylated baboon IgG, and processed with avidin-HRP and enhanced chemiluminescence (ECL). Similarly, filters containing serial dilution of etanercept were challenged with biotinylated baboon IgG to detect anti-TNFRII-Fc (see online Supplementary information).
Histology and immunofluorescent microscopy
Frozen mouse tissues were challenged with anti-human IgG-Fc fragment (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Zinc formalin-fixed baboon tissues were stained with H&E, and reviewed by a pathologist blinded to treatment groups (EK). Frozen-fixed specimens were challenged with mouse anti-human CD8 (Pharmingen, Torrey Pines, CA, USA) followed by Cy-3-labeled goat anti-mouse, and costained with 4,6-diamidino-2-phenylindole (DAPI) to identify nuclei and Alexa fluor 488 phalloidin (Molecular Probes, Carlsbad, CA, USA) to identify filamentous actin. Slides were viewed at 20 and Â 40 with a confocal microscope (see online Supplement information for details).
Statistical analyses
Data is reported as mean7s. 
